2017
DOI: 10.1093/cid/cix977
|View full text |Cite
|
Sign up to set email alerts
|

Deployment of Transchromosomal Bovine for Personalized Antimicrobial Therapy

Abstract: For decades, intravenous immunoglobulin (IVIg) has provided safe and effective therapy for immunodeficient patients. This proof-of-principle study describes a novel approach to generate personalized IVIg for chronic, antibiotic-resistant infection in real time.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
11
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
8

Relationship

4
4

Authors

Journals

citations
Cited by 10 publications
(11 citation statements)
references
References 10 publications
0
11
0
Order By: Relevance
“…SAB-136 was safe and efficacious in a phase I clinical trial that treated a patient with severe immunodeficiency, hypogammaglobinemia, and chronic M hominis septic hip and polyarthritis. The patient received SAB-136 for 1 year, and the drug was well tolerated with no significant adverse events and displayed and his clinical parameters improved with decreased mycoplasma burden [19].…”
mentioning
confidence: 96%
“…SAB-136 was safe and efficacious in a phase I clinical trial that treated a patient with severe immunodeficiency, hypogammaglobinemia, and chronic M hominis septic hip and polyarthritis. The patient received SAB-136 for 1 year, and the drug was well tolerated with no significant adverse events and displayed and his clinical parameters improved with decreased mycoplasma burden [19].…”
mentioning
confidence: 96%
“…SAB-136 was safe and efficacious in a phase I clinical trial that treated a patient with severe immunodeficiency, hypogammaglobinemia, and multiyear chronic M hominis septic hip and polyarthritis. The patient received SAB-136 for 1 year, and the drug was well tolerated with no significant adverse events and displayed improved clinical parameters with decreased mycoplasma burden [8]. Previously, a codon optimized EBOV GP deoxyribonucleic acid (DNA) vaccine and a recombinant GP (rGP) nanoparticle vaccine were used to immunize TcB that resulted in production of EBOV GP neutralizing antibodies, which provided partial protection in mice when passively administered after lethal EBOV challenge [9,10].…”
mentioning
confidence: 99%
“…It is worth noting that TcB derived fully human polyclonal antibodies elicited against several other viruses or bacteria have been shown to be effective to treat infections caused by various infectious pathogens [5,6,11,28,29,30,31]. Some of these TcB antibodies have already been proven to be safe and efficacious in human clinical trials [31,32]. The anti-ZIKV TcB antibodies reported in this study are yet to be tested in rigorous human clinical trials to be proven effective in treating ZIKV in human infections.…”
Section: Discussionmentioning
confidence: 99%